Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Retained Earnings (2019 - 2025)

Avidity Biosciences' Retained Earnings history spans 7 years, with the latest figure at -$1.6 billion for Q4 2025.

  • For Q4 2025, Retained Earnings fell 79.16% year-over-year to -$1.6 billion; the TTM value through Dec 2025 reached -$1.6 billion, down 79.16%, while the annual FY2025 figure was -$1.6 billion, 79.16% down from the prior year.
  • Retained Earnings reached -$1.6 billion in Q4 2025 per RNA's latest filing, down from -$1.3 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $7.1 million in Q3 2024 to a low of -$1.6 billion in Q4 2025.
  • Average Retained Earnings over 5 years is -$452.2 million, with a median of -$308.1 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: skyrocketed 101.39% in 2024, then tumbled 264800.66% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$187000.0 in 2021, then crashed by 191634.76% to -$358.5 million in 2022, then plummeted by 59.19% to -$570.8 million in 2023, then crashed by 56.47% to -$893.1 million in 2024, then tumbled by 79.16% to -$1.6 billion in 2025.
  • Per Business Quant, the three most recent readings for RNA's Retained Earnings are -$1.6 billion (Q4 2025), -$1.3 billion (Q3 2025), and -$1.2 billion (Q2 2025).